Work

Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.3_suppl.573

Authors: Kentaro Yamazaki, Takayuki Yoshino, Katsuya Tsuchihara, Eiji Shinozaki, Kei Muro, Tomohiro Nishina, Kensei Yamaguchi, Kiwamu Akagi, Satoshi Yuki, Takeharu Yamanaka, Shogo Nomura, Satoshi Fujii, Hiroyasu Esumi, Yukiko Abe, Atsushi Ohtsu

Institutions: Shizuoka Cancer Center, National Cancer Center Hospital East, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Aichi Cancer Center, Aichi Cancer Center Hospital, Shikoku Cancer Center, Saitama Cancer Center, Hokkaido University Hospital, National Cancer Centre Japan, National Cancer Center Hospital, Tokyo University of Science, Research Institute for Biomedical Sciences, Tokyo University of Science, G&G Science Co., Ltd. (Japan)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2590930747

Cites:

Cited by: 4

Related to: 10